Skip to main navigation

Vivek Ramaswamy

Founder & CEO

Roivant Sciences

About Us
Pipeline
Our Companies
For Investors +
Join Us

Press Releases

Year

September 10, 2024

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

September 9, 2024

Roivant Provides Update on Graves’ Disease Development Program

August 8, 2024

Roivant Reports Financial Results for the First Quarter Ended June 30, 2024, and Provides Business Update

July 25, 2024

Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024

May 30, 2024

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

May 16, 2024

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024

April 2, 2024

Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million

February 13, 2024

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2023, and Provides Business Update

January 30, 2024

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024

Print Page
Email Alerts
RSS Feeds
IR Contacts

© 2024 Roivant Sciences Ltd.

Careers Privacy Policy

Follow us on LinkedIn